Difference between revisions of "Lung carcinoma with EGFR mutation"

Lung carcinoma with EGFR mutation (view source)

390 bytes added , 17:58, 18 June 2017

no edit summary

48,868

edits

@@ Line 1: / Line 1: @@
-'''Lung adenocarcinoma with EGFR rearrangement''' is a molecular subtype of [[lung adenocarcinoma]].
+'''Lung adenocarcinoma with EGFR mutation''' is a molecular subtype of [[lung adenocarcinoma]].
 ==General==
@@ Line 5: / Line 5: @@
 **Testing done together with ALK.
 *EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal  | last1 = Gainor | first1 = JF. | last2 = Varghese | first2 = AM. | last3 = Ou | first3 = SH. | last4 = Kabraji | first4 = S. | last5 = Awad | first5 = MM. | last6 = Katayama | first6 = R. | last7 = Pawlak | first7 = A. | last8 = Mino-Kenudson | first8 = M. | last9 = Yeap | first9 = BY. | title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. | journal = Clin Cancer Res | volume = 19 | issue = 15 | pages = 4273-81 | month = Aug | year = 2013 | doi = 10.1158/1078-0432.CCR-13-0318 | PMID = 23729361 }}</ref>
+Treatement:<ref name=pmid20887192>{{Cite journal  | last1 = da Cunha Santos | first1 = G. | last2 = Shepherd | first2 = FA. | last3 = Tsao | first3 = MS. | title = EGFR mutations and lung cancer. | journal = Annu Rev Pathol | volume = 6 | issue =  | pages = 49-69 | month =  | year = 2011 | doi = 10.1146/annurev-pathol-011110-130206 | PMID = 20887192 }}</ref>
+*[[Tyrosine kinase inhibitors]].
 ===Associations===